变应性鼻炎免疫治疗疗效、安全性与依从性的Meta分析
该Meta分析比较皮下免疫治疗(SCIT)与舌下免疫治疗(SLIT)治疗变应性鼻炎的疗效、安全性和依从性,纳入20项随机对照研究。结果显示两组在鼻部症状评分、VAS评分及依从性上差异无统计学意义,SLIT总体不良反应发生率低于SCIT。
要点
- SCIT与SLIT改善鼻部症状及VAS评分的效果相似。
- 两种免疫治疗依从性差异无统计学意义。
- SLIT总体不良反应发生率低于SCIT。
核心结论
- SCIT与SLIT治疗变应性鼻炎的疗效及依从性相似,但SLIT不良反应发生率较低。
研究设计与样本
- Meta分析,检索Cochrane Library、PubMed、Embase、CNKI、万方及中国科技期刊全文数据库至2018年5月,纳入20项随机对照研究。
主要发现
- 鼻部症状评分组间差异无统计学意义,SMD=0.03,95%CI -0.17~0.23,P>0.05。
- VAS评分组间差异无统计学意义,SMD=0.14,95%CI -0.03~0.31,P>0.05。
- 依从性组间差异无统计学意义,RR=1.12,95%CI 0.92~1.35,P>0.05。
- SLIT组总体不良反应发生率低于SCIT组,RR=1.79,95%CI 1.42~2.26,P<0.05。
关键数值与推荐
- 以鼻部症状评分、VAS评分、不良反应及依从性为结局指标。
- 纳入文献整体质量相对较高,未提示明显发表偏倚。
临床怎么用
- 为变应性鼻炎选择免疫治疗方式时,可结合疗效、依从性与不良反应风险个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: By use of Meta analysis to compare efficacy, safety and compliance of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) on allergic rhinitis (AR). Methods: Cochrane Library, Pubmed, Embase, CNKI Database, Wan Fang and Chinese Sci-tech Journal Database (from established time to May of 2018) were searched for trials about the AR treated by SCIT and SLIT. The relevant literatures were screened, and the randomized controlled studies were chosen. Nasal symptom scores, visual analogue scale (VAS) scores, adverse reactions and compliance were used as the outcome indicators, and the methodological quality of the literatures was evaluated strictly. The extracted data were analyzed by RevMan 5.3 and Stata 14 software. Results: A total of 20 randomized controlled studies were included, the overall quality of which was relatively high. No publication bias was found. There was no significant difference in nasal symptom scores, VAS scores and compliance between SCIT and SLIT (SMD value was 0.03, 0.14, respectively, RR=1.12; 95%CI value was -0.17-0.23, -0.03-0.31, 0.92-1.35, respectively, all P>0.05); SLIT group resulted in lower overall incidence of adverse reactions than that of SCIT group (RR=1.79, 95%CI: 1.42-2.26, P<0.05). Conclusion: Both SCIT and SLIT have similar eppecacy and compliance for treatment of AR, while adverse reactions are more frequently observed in SCIT. 目的: 使用Meta分析的方法,比较皮下免疫治疗(subcutaneous immunotherapy,SCIT)与舌下免疫治疗(sublingual immunotherapy,SLIT)在治疗变应性鼻炎(allergic rhinitis,AR)中的疗效、安全性及依从性差异。 方法: 在Cochrane Library、PubMed、Embase等外文数据库和中国知网(CNKI)、万方数据库、中国科技期刊全文数据库等中文文献数据库中,检索从建库至2018年5月发表的所有采用SCIT及SLIT治疗AR的文献并进行筛选,选取随机对照研究,以鼻部症状评分、视觉模拟量表(visual analogue scale,VAS)、不良反应及依从性为结局指标,对纳入文献进行严格质量评价并提取资料,使用RevMan 5.3及Stata 14软件合并数据。 结果: 纳入20篇随机对照研究,整体文献质量相对较高,未提示明显发表偏倚。Meta分析结果显示SCIT组与SLIT组在改善鼻部症状评分、VAS评分、依从性方面的差异均无统计学意义(SMD值分别为0.03、0.14,RR值为1.12;95%CI分别为-0.17~0.23、-0.03~0.31、0.92~1.35,P值均>0.05);SLIT组总体不良反应发生率低于SCIT组(RR=1.79,95%CI:1.42~2.26,P<0.05)。 结论: SCIT与SLIT应用于AR患者疗效及依从性相似,但SLIT不良反应发生率较低。.
引用
- Ji DX, Tan JR, Yu HW, et al. [Efficacy, safety and compliance of immunotherapy in the treatment of allergic rhinitis: a Meta-analysis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019. PMID: 31887814. doi:10.3760/cma.j.issn.1673-0860.2019.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。